|
SIGNIFICANT CONCENTRATIONS (Details) (USD $)
In Thousands, unless otherwise specified |
12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2013
Revenues
Customer concentration
AstraZeneca
|
Dec. 31, 2012
Revenues
Customer concentration
AstraZeneca
|
Dec. 31, 2013
Revenues
Customer concentration
Daiichi
|
Dec. 31, 2012
Revenues
Customer concentration
Daiichi
|
Dec. 31, 2012
Revenues
Customer concentration
BerGenBio
|
Dec. 31, 2011
Revenues
Customer concentration
BerGenBio
|
Dec. 31, 2011
Revenues
Customer concentration
Merck Serono
|
Dec. 31, 2013
Accounts receivable
Credit risk concentration
AstraZeneca
|
|
| SIGNIFICANT CONCENTRATIONS | |||||||||
| Concentration risk as a percentage of revenue | 80.00% | 44.00% | 20.00% | 33.00% | 22.00% | 11.00% | 89.00% | ||
| Accounts receivable | $ 5,750 | $ 5,800 | |||||||